期刊簡介 | |||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱 | HLA LetPub Score 6.3
50 ratings
Rate
Reputation 7.3 Influence 4.9 Speed 9.1 | ||||||||||||||||||||||||
期刊簡稱 | HLA | ||||||||||||||||||||||||
ISSN | 2059-2302 | ||||||||||||||||||||||||
E-ISSN | 2059-2310 | ||||||||||||||||||||||||
h-index | 93 | ||||||||||||||||||||||||
CiteScore |
| ||||||||||||||||||||||||
自引率 (2023-2024) | 40.70%自引率趨勢 | ||||||||||||||||||||||||
掲載範囲 |
| ||||||||||||||||||||||||
官方網站 | https://onlinelibrary.wiley.com/journal/20592310 | ||||||||||||||||||||||||
在線稿件提交 | https://mc.manuscriptcentral.com/hla | ||||||||||||||||||||||||
開放訪問 | No | ||||||||||||||||||||||||
出版商 | Wiley-Blackwell Publishing Ltd | ||||||||||||||||||||||||
主題領域 | Immunology and Microbiology | ||||||||||||||||||||||||
出版國/地區 | UNITED STATES | ||||||||||||||||||||||||
發行頻率 | |||||||||||||||||||||||||
創刊年 | 0 | ||||||||||||||||||||||||
每年文章數 | 94每年文章數趨勢 | ||||||||||||||||||||||||
黃金OA百分比 | 32.47% | ||||||||||||||||||||||||
Web of Science 四分位 ( 2023-2024) | WOS Quartile: Q1
| ||||||||||||||||||||||||
索引 (SCI or SCIE) | Science Citation Index Science Citation Index Expanded | ||||||||||||||||||||||||
鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=2059-2302%5BISSN%5D | ||||||||||||||||||||||||
平均審稿時間 * | 來自出版商的數據: 來自作者的數據: | ||||||||||||||||||||||||
競爭力 * | 來自作者的數據: | ||||||||||||||||||||||||
參考鏈接 |
| ||||||||||||||||||||||||
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。 |
|
首頁 上一頁 1 下一頁 末頁 (頁 | |
[HLA] 的評論 | 撰寫評論 |
作者: 坠星振英 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-10-21 15:39:12 評論於 Review speed: 3.0 | Submission hit rate: 25.0 Emphasized research directions: Cell Biology; Immunology; Pathology Experience sharing: European Federation for Immunogenetics (EFI) official journal, issued 12 times a year, edited by Professor Steven GE Marsh of the Anthony Nolan Research Institute in the UK. Journal categories: Cell Biology, Immunology, Pathology JCR Category: Cell Biology Zone 1, Immunology Zone 1, Pathology Zone 1 CAS Category: Major Category: Zone 4 Minor Category: Cell Biology Zone 4, Immunology Zone 4, Pathology Zone 4 Is it a TOP journal: No Scope of submission: Immunogenetics of cell surface antigens; Individual and systemic development of the immune system; Immunogenetics of cell interactions; Functional aspects of cell surface molecules and their natural ligands, such as cytokines, adhesion molecules, and activation antigens; The role of tissue antigens in in vitro and in vivo immune responses, including experimental and clinical transplantation; The relationship between normal tissue antigens and tumor-associated antigens. The main forms of articles are Meeting, Other, Article, Abstract, Review, Editorial Material, Letter. Impact Factor HLA has not had an impact factor for long, obtaining its first impact factor in 2016. Since then, the journal has been diligent, with the impact factor increasing year by year, and breaking through to 8 points this year. The SCI impact factors from 2017 to 2021 were 2.558, 2.785, 2.955, 4.513, 8.762. However, this journal has been around for a long time and has been renamed. Quantity of articles and Chinese authors' publication situation The number of articles in HLA from 2017 to 2021 were 531, 565, 636, 697, 436. The number of articles published over these four years rose significantly from 2017 to 2020, but decreased in 2021, with overall article quantity being considerable. Looking at the statistics for 2021, Chinese authors published 61 articles in HLA, accounting for 13.991%, ranking second, and being relatively friendly to Chinese authors, with France ranking first. Some Chinese units with more publications are Zhejiang Blood Center (19), Shenzhen Blood Center (13), HLA Tissue Typing Laboratory (7) Review period Looking at several recently published articles, the average review period is around 2-3 months, and the publishing speed is very fast. Publishing mode and fees According to the official website information, HLA is a hybrid/reform journal. Authors can choose the traditional subscription mode, with no page fees, or the OA mode, with a page fee of $4,200, approximately RMB 28,399. Self-citation rate HLA's self-citation rate in the past five years has been within the range of 0-40%, with it being 30.8% in 2021, which is relatively high so caution is needed! Overall evaluation As a journal in the medical field, HLA's impact factor has been steadily increasing over the past five years, with fast review speeds, being friendly to Chinese authors, not charging any fees for traditional subscription mode, but having a relatively high self-citation rate which can be risky. Friends who are interested may consider preparing for this journal!(0) 讚! | 坠星振英 |
作者: 喜羊羊 領域: 医学 審稿時間: 3.0 month(s) 結果: 修改後接受 撰寫評論 |
2018-08-17 17:15:31 評論於 The first year of IF is quite high, just one in July, and now it’s beautiful.(0) 讚! | 喜羊羊 |
作者: 通背光磊 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2018-08-17 10:57:27 評論於 Review speed: 3.0 | Submission hit rate: 50.0 Sharing experience: In the first year, it's quite good. I just had an article accepted in July, and now I'm feeling great(0) 讚! | 通背光磊 |
作者: 通幽以琴 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2017-11-02 11:33:15 評論於 Half a year has passed. Everything is going as expected. Lin Jinming published on May 8, 2017: SCI (2015): 2.046 SCI (2014): 2.137 Too slow. No news in half a year. Everyone, please pay attention(0) 讚! | 通幽以琴 |
作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2017-07-18 15:50:02 評論於 It's frustrating that I got over 2 points for my publication last year, but this year it's just over 1 point. Will it decrease even more next year? Who would want to invest in it?(0) 讚! | 凌霄高洁 |
作者: 通幽以琴 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2017-05-08 18:29:16 評論於 Too slow, no news for half a year, everyone pay attention(0) 讚! | 通幽以琴 |
作者: 神古苑博 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2016-06-27 18:38:08 評論於 Review Speed: 3.0 | Submission Acceptance Rate: 75.0 Experience sharing: Renamed to HLA since 2016, and it has been troublesome ever since. I don't know why these journals keep changing their names, it's really annoying(0) 讚! | 神古苑博 |
作者: 明冠宏儒 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2016-06-27 15:39:57 評論於 It was renamed to "HLA" in 2015(0) 讚! | 明冠宏儒 |
作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2013-07-01 17:02:23 評論於 This journal is now rated at 2.5, a significant increase from last year. Is there a possibility of reaching a score of 3?(0) 讚! | 凌霄高洁 |
作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2011-06-29 17:04:42 評論於 Bullish, if it rises a bit more tomorrow, it may break through 3 points(0) 讚! | 凌霄高洁 |
首頁 上一頁 1 下一頁 末頁 (頁 |
Contact us